ADMA Biologics (NASDAQ:ADMA) Stock Price Down 6.8% After Insider Selling

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s stock price fell 6.8% on Tuesday after an insider sold shares in the company. The company traded as low as $19.17 and last traded at $19.01. 1,700,847 shares changed hands during trading, a decline of 54% from the average session volume of 3,667,821 shares. The stock had previously closed at $20.40.

Specifically, Director Steve Elms sold 92,941 shares of the stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $21.69, for a total transaction of $2,015,890.29. Following the sale, the director now owns 2,031,730 shares in the company, valued at approximately $44,068,223.70. This represents a 4.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director now owns 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The disclosure for this sale can be found here. In other news, Director Steve Elms sold 137,931 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $20.82, for a total transaction of $2,871,723.42. Following the transaction, the director now owns 282,079 shares of the company's stock, valued at $5,872,884.78. This represents a 32.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Raymond James upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $24.25.

ADMA Biologics Stock Performance

The stock has a 50 day moving average price of $20.99 and a two-hundred day moving average price of $18.83. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a market cap of $4.51 billion, a price-to-earnings ratio of 67.55 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same period in the previous year, the company posted $0.08 EPS. The company's quarterly revenue was up 40.2% compared to the same quarter last year. Analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds have recently added to or reduced their stakes in ADMA. Van ECK Associates Corp acquired a new position in ADMA Biologics in the fourth quarter valued at about $3,424,000. New York State Teachers Retirement System raised its position in shares of ADMA Biologics by 24.1% during the fourth quarter. New York State Teachers Retirement System now owns 113,090 shares of the biotechnology company's stock worth $1,939,000 after purchasing an additional 21,976 shares during the period. Rhumbline Advisers raised its position in shares of ADMA Biologics by 1.0% during the fourth quarter. Rhumbline Advisers now owns 621,079 shares of the biotechnology company's stock worth $10,651,000 after purchasing an additional 5,881 shares during the period. Principal Financial Group Inc. raised its position in shares of ADMA Biologics by 5.4% during the fourth quarter. Principal Financial Group Inc. now owns 1,259,014 shares of the biotechnology company's stock worth $21,592,000 after purchasing an additional 64,793 shares during the period. Finally, D.A. Davidson & CO. acquired a new stake in shares of ADMA Biologics during the fourth quarter worth about $202,000. Institutional investors and hedge funds own 75.68% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.